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COMPAbstract Objective: To evaluate the chondroprotective effect of L-carnitine in relation to
glucosamine sulfate and in an experimental model of osteoarthritis (OA).
Materials and methods: Thirty-two adult male Wister albino rats weighing 150–210 g were assigned
randomly into 4 groups: 8 rats in each group, group I (control group), group II (MIA induced OA
group), group III (MIA induced OA + glucosamine sulfate treated group), and group IV (MIA
induced OA + L-carnitine treated group). Weight, knee diameter, and knee bend score were
recorded on days 0, 1, 7, 14 and 28. On day 28 all animals were sacrificed. Synovial fluid of left knee
was collected, and the interleukin-1b (IL-1b), Cartilage oligomeric matrix protein (COMP) and
matrix metalloproteinase-13 (MMP-13) levels were measured by ELISA. The knee joints were
removed and stained with H&E for histological evaluation.
Results: The pathological abnormalities attributed to MIA induced arthritis was dramatically low-
ered in rats treated with glucosamine or L-carnitine. Synovial fluid levels of IL-1b, COMP and
MMP-13 were increased in OA group, and significantly reduced with glucosamine or L-carnitine
treated groups.
Conclusion: L-Carnitine has a potential chondroprotective effect in this animal model of OA.
 2016 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Osteoarthritis1 is one of the most common forms of degenera-
tive joint disease and a major cause of pain and disability
affecting the aging population. Several factors including
genetic susceptibility, obesity, injuries and inflammation of
the joint have been long considered as important risk factors
of the disease.2
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synthesis and degradation of extracellular matrix [ECM] com-
ponents is maintained.3 In osteoarthritic states, however, a dis-
ruption of matrix equilibrium leads to cartilage degradation,
induction of oxidative states, and eventually, apoptosis of
chondrocytes.4 The triggering events and exact pathologic
mechanism that result in cartilage loss and degradation are
not completely understood. It has been suggested that inflam-
matory mediators such as cytokines [IL-1b, TNFa, IL-6, IL-8,
and IL-17], chemokine and reactive oxygen species5 have a pri-
marily destructive impact on articular cartilage.3 These inflam-
matory mediators lead to increase synthesis and release of
matrix metalloproteinases [MMPs] and cartilage degradation.6
Analgesics and non-steroidal anti-inflammatory drugs
[NSAIDs] are the main therapeutic treatment options for
OA. Unfortunately, these medications are short-term and fail
to adequately address pathophysiological and biochemical
mechanisms involved with cartilage degeneration and the
induction of pain in arthritic joints.7 The search for effective
treatment/dietary supplements able to slow the progression
of disease seems warranted.
L-Carnitine [LC] [3-hydroxy-4-N-trimethylaminobutyrate],
the bioactive form of carnitine, is an endogenous branched
nonessential amino acid derivative that plays a critical role
in energy production. It transports long-chain fatty acids from
the cytoplasm to mitochondria so they can be oxidized to pro-
duce energy.8 L-Carnitine bioavailability is 5–18%9 and elimi-
nated from the body mainly via urinary excretion.10 L-
Carnitine has been shown to offer a great therapeutic potential
against several chronic conditions including cardiovascular,
diabetes, neurodegenerative, and inflammatory diseases.11
High dose can cause nausea, vomiting, abdominal cramps,
diarrhea, a ‘‘fishy” body odor and rarely muscle weakness
and seizures.12
Glucosamine [GA] naturally occurring 6-carbon amino
sugar, normally found in the body.13 The oral bioavailability
of glucosamine is about 26%. It is distributed to liver, kidney
and other tissues including articular cartilage.14 The mecha-
nism of action of glucosamine is unknown. Glucosamine was
demonstrated to reverse the deleterious effects of IL-1b,
nuclear factor-jB and prostaglandin E2.15 Glucosamine
appears to be safe, with possibility of causing allergic reaction
and possibly increasing the risk of developing diabetes.16
Unilateral intra-articular [i.a.] injection of mono-
iodoacetate17, a chondrocyte glycolytic inhibitor, has been
used to induce osteoarthritis-like changes in the articular car-
tilage of rodents. This minimally invasive model reproduces
cartilage lesions with loss of proteoglycan matrix and func-
tional joint impairment similar to human OA.3
In this study, knee bend test, histological examination of
knee joints, in addition to synovial fluid levels of interleukin-
1b [IL-1b], and matrix metalloproteinase-13 [MMP-13] were
estimated to evaluate the effect of L-carnitine, as compared
to glucosamine sulfate,18 in a rat model of MIA induced OA.
2. Materials and methods
2.1. Animals
Thirty-two adult male Wister rats weighing 150–210 g at the
start of the experiment were purchased from Moassat AnimalHouse [Faculty of Medicine, Alexandria University]. Animals
were fed standard rat chow with free access to water, and were
acclimatized for 2 weeks before the experiment. The study pro-
tocol was approved by the Ethics Committee, Faculty of Med-
icine; Alexandria University, Egypt.
2.2. MIA-induced OA
OA was induced in rats [pre-anesthetized with ether] by a sin-
gle intra-articular injection of 2 mg of mono-iodoacetate
[MIA, Sigma-Aldrich, St. Louis, MO, USA] through the infra-
patellar ligament into the joint space of the left knee, in a total
volume of 25 ll saline, via a 26.5-G needle.19 Control rats were
injected with an equivalent volume of saline.
2.3. Animal grouping
Rats were assigned randomly into four groups, 8 rats in each
group, as follows: Group I [control group], group II [MIA
induced OA group], group III [MIA induced OA/glucosamine
sulfate, 250 mg/kg/day, treated group],20 and group IV [MIA
induced OA/L-carnitine, 100 mg/kg, treated group].21
2.4. Knee diameter
Knee diameter was measured using calibrated digital caliper
[World Precision Instruments, Stevenage, UK] in millimeter
[mm] to assess the developmental stages of OA on days 0
[pre MIA injection], 1, 7, 14, 21, and 28 [post injection].22
2.5. Knee bend test
The Knee-bend test was done at days 0, 1, 7, 14, 21 and 28 to
evaluate the movement-induced pain caused by MIA. Briefly,
we recorded the squeaks and/or struggle reactions in response
to five alternate flexion and extensions of the knee joint [per-
formed within the physiological limits of knee flexion/exten-
sion] for each rat. The score of the test was determined as
follows: 0 – no responses; 0.5 – struggle to maximal flexion/
extension; 1 – struggle to moderate flexion/extension or vocal-
izations to maximal flexion/extension; 2 – vocalizations to
moderate flexion/extensions. The sum of the animal’s reac-
tions, giving maximal values of 20, represents the Knee-Bend
score, an indication of the animal’s movement-induced noci-
ception. The contralateral knee was always tested first, in order
to avoid an increase in the contralateral score arising from the
manipulation of the injected knee. Results for both ipsilateral
and contralateral knees were presented.23
2.6. Biochemical analysis
On day 28, rats were anaesthetized with Thiopental sodium
40 mg/kg24 intraperitoneally.18 The left limb of the rat was
flexed over a 20 ml glass vial, then 23-gauge needle was
inserted, and the limb was secured in place with tape. Sterile
saline was infused intra-articularly. 2 min after infusion of
100 ll of saline, the outflow fluid was aspirated. Synovial fluid
was infused and withdrawn at a constant rate until a 400 ll
basal sample was collected in a 1.5 ml centrifuge tube. Samples
were immediately centrifuged, and the supernatants were
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were estimated in the synovial fluid using ELISA kits:
[IL-1b] [BMS630, eBioscience, Inc., Vienna, Austria],
[MMP-13] [SCA099Ra Uscn Life Science Inc., Houston,
USA], and Cartilage oligomeric matrix protein [COMP]
[SEB197Ra, Uscn Life Science Inc., Houston, USA].4,25
Briefly, micro well strips for IL-1b, MMP-13, and COMP
were washed with wash buffer. Standard curve solution was
added to standard curve wells, 50 ml of sample serum
+50 ml sample diluent and 50 ml of biotin conjugate were
mixed together [mixture A] and added to the wells and incu-
bated for 2 h at room temperature. Mixture A was removed,
wells were washed and 100 ml of diluted Streptavidin-HRP
[mixture B] was added and incubated for 1 h at room temper-
ature with gentle agitation. Mixture B was removed, wells were
washed and 100 ml of TMB substrate solution was added to
the wells and incubated for 20 min at room temperature with
gentle agitation until the highest standard curve point had
developed [dark blue color]. Enzymatic reaction was stopped
by the addition of 100 ml of stop solution. Plates were read
on a spectrophotometer using 450 nm reference wavelengths,
and cytokine concentration was determined from the standard
curve. All samples and standards were run in triplicate.
2.7. Histopathological analysis
The knee joints of the rats were excised, and the soft tissues
around it were removed. The knee joints were fixed in 10%
buffered formalin, decalcified in hydrochloric acid, and embed-
ded in paraffin. Sections [10 lm in thickness] were stained with
hematoxylin and eosin [H&E].26
2.8. Statistical analysis
Values are expressed as the mean ± SD. Statistical analyses
were done using the Statistical Package of Social Sciences
[SPSS] version 20. The IL-1b, COMP, MMP-13 levels were
tabulated and analyzed statistically by one-way ANOVA, fol-
lowed by a Post Hoc [Scheffe] test to compare variables
between different groups. While the weight, knee diameterTable 1 Left knee diameter (mm), and knee bend score, for the stu
Groups Days
1












Note: Group I, normal control group; Group II, untreated MIA-induced
Group IV, MIA-induced OA rats treated with carnitine; F, ANOVA test;
significant with group II.and knee bend score were tabulated and analyzed statistically
using repeated measures ANOVA test. p values of less than
0.05 were considered significant.27
3. Results
3.1. Weight
Rats in group II, III and IV had a decrease in weight gain com-
pared to control group, in first week post-MIA induction. On
day 28 all studied groups had almost same weight.
3.2. Knee diameter, Table 1
There was a significant increase in left knee diameter in groups
II, III and IV as compared to normal control group [p < 0.05].
The maximal diameter was recorded on day 7 post-MIA injec-
tions. Treatment with GA or LC resulted in significant
decrease in left knee diameter as compared to non-treated
OA-induced group.
3.3. Knee bends score, Table 1
No sign of spontaneous nociceptive behavior or distress was
found before MIA injection. Meanwhile, there was a signifi-
cant increase in knee bend score in groups II, III and IV as
compared to their baseline values, and to the normal control
values [p< 0.05]. Treatment with GA or LC resulted in non
significant decrease, in day 14, in knee bend score when com-
pared to OA induced group.
3.4. Biochemical markers
3.4.1. IL-1b level, Table 2
IL-1b level was significantly increased in S.F from animals in
group II as compared to group I [149.3 ± 3 pg/ml, 56.2
± 19.7 pg/ml respectively, p< 0.05]. Meanwhile, statistically
significant lower levels of IL-1b were obtained when MIA
treated rats received either glucosamine or L-carnitinedied groups.
7 14 21 28
0.917 0.918 0.918 0.918
1.183a 1.133a 1.117a 1.067a
1.014ab 1.013ab 1.01ab 1ab
1.011ab 1.056ab 1.033ab 1.033
<0.05* <0.05* <0.05* <0.05*
3.48 5.412 3.772 3.387
1.7 1.6 1.6 1.6
14.2a 5.83a 5.8 a 4.17
5.57ab 5.43a 5.71a 2.14
5.56b 5.56 4.44 3.33
<0.001* 0.08 <0.05* 0.28
14.245 1.738 4.334 1.35
OA rats; Group III, MIA-induced OA rats treated with glucosamine;
* indicates statistical significance; a, significant with normal group; b,
Table 2 Levels of IL-1b (pg/ml), COMP (ng/ml), and MMP-
13 (ng/ml) in the studied groups.
Parameter IL-1b (pg/ml) COMP (ng/ml) MMP-13 (ng/ml)
Group I 56.2 ± 19.7 53.1 ± 14 2.4 ± 1
Group II 149.3 ± 3a 188.2 ± 21.7a 9 ± 3.6a
Group III 65.2 ± 17.7b 150.4 ± 9.6b 3.1 ± 1.1b
Group IV 76.2 ± 17b 108.9 ± 15.2b 3.4 ± 1.2b
p-value <0.001* <0.001* <0.001*
F 43 71 13
Note: Group I, normal control group; Group II, untreated MIA-
induced OA rats; Group III, MIA-induced OA rats treated with
glucosamine; Group IV, MIA-induced OA rats treated with car-
nitine; F, ANOVA test.
* Indicates statistical significance.
a Significant with group I.
b Significant with group II.
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compared to group II].
3.4.2. COMP level, Table 2
COMP, a marker of joint destruction, was dramatically
increased in cartilage from group II rats [171.2 ± 26.6 ng/ml]
as compared to group I [53.1 ± 14 ng/ml]. Treatment with
glucosamine sulfate or L-carnitine caused a significant decrease
in COMP levels [150.4 ± 9.6 ng/ml and 108.9 ± 15.2 ng/ml
respectively p< 0.05 when compared to group II].
3.4.3. MMP-13 level, Table 2
There was a significant increase in MMP-13 level in cartilage in
group II [9 ± 3.6 ng/ml] as compared to group I [2.4 ± 1 ng/Figure 1 Histological findinml], whereas treatment with glucosamine sulfate or L-
carnitine significantly abrogated this increase [3.1 ± 1.1 and
3.4 ± 1.2 respectively, p < 0.05 vs group II].
3.5. Histological findings, Figs. 1 and 2
The isolated knee joints from the normal control group
showed a smooth surface of the articular cartilage, with nor-
mal cellularity. In contrast, the joints from the MIA-induced
OA rats showed joint space narrowing decrease in cartilage
thickness, with irregular fibrillated surface, abnormal matrix
intensity and chondrocytes.
Histological signs of cartilage degradation were reduced in
GS, or LC treated groups. Preservation of cartilage smooth
surface with almost normal thickness and matrix intensity
was observed in both groups, and subchondral bone appeared
with increased vascularization.
As shown in Fig. 1 [A] Group I light photomicrograph of
rat knee joint of control group shows cartilage with smooth
non-fibrillated superficial region, matrix and scattered chon-
drocytes ["]. Subchondral bone appears with more basophilic
staining matrix [*] enclosing bone trabeculae. [H&E stain.
Mic. Mag. 100.]
[B] Group II light photomicrograph of rat knee joint of
induced osteoarthritis group reveals significant difference in
articular cartilage thickness with irregular fibrillated surface,
abnormal matrix intensity and chondrocytes. Subchondral
bone shows irregularity in matrix and shape. Notice pannus
formation [P] a hyperplastic synovial villus extends over the
surface of the articular cartilage as a fibrous inflammatory
membrane. [H&E stain. Mic. Mag. 100.]
[C] Group III light photomicrograph of rat knee joint of
glucosamine sulfate treated group depicts recovery of knee joint
with preservation of cartilage smooth surface with normalgs of all studied groups.
Figure 2 Histopathologic evaluation of knee cartilage from
control (group 1), MIA-induced OA (group II), GS (group III)
and LC (group IV). OARSI grading range from 1 to 6, where 1 is
normal cartilage and 6 total loss of cartilage. Total mankin score is
a sum of the scores for cartilage structure, cellular abnormalities,
tideline and matrix Staining with toluidine blue, and total score of
15 means severe damage of cartilage while 0 means normal
cartilage. According to OARSI and mankin score, both GS an LC
groups show significant difference when compared to group II
(p< 0.05) * = significant difference compared to group II.
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increased vascularization. [H&E stain. Mic. Mag. 100.]
[D] Group IV light photomicrograph of rat knee joint of
L-carnitine treated group depicts partial recovery of knee joint
with preservation of cartilage smooth surface but decreases in
its thickness and matrix intensity. Subchondral bone appears
with increased vascularization. [H&E stain. Mic. Mag. 100.]
4. Discussion
Osteoarthritis is a degenerative joint disease characterized by
the progressive loss of cartilage, changes in subchondral bone,
and chronic pain. Analgesics and non-steroidal anti-
inflammatory drugs [NSAIDs] are the main therapeutic treat-
ment options for OA. The search for treatments able to slow
the progression of disease is a great challenge and would meet
an important medical need for patients with OA.
The development and progression of OA are now believed
to involve inflammation, even in the early stage.1 Proinflamma-
tory cytokines and chemokine play critical roles in disturbed
homeostasis in the OA cartilage matrix. Interleukin-1b
[IL-1b] among them plays a crucial role in the downregulation
of the synthesis of major ECM components by inhibiting ana-
bolic activities and increasing catabolic activities in chondro-
cytes.28 Furthermore, IL-1b decreases the synthesis of a
number of cytokines which contribute to inflammation, includ-
ing IL-6 and IL-8.6
The MIA-induced OA animal model used in the present
study is a well-characterized model and mimics pain and bio-
chemical/structural changes associated with human OA. In
our study, we demonstrated that the synovial fluid level of
IL-1b was increased in the untreated MIA induced OA group.
On the other hand, synovial fluid levels of IL-1b were signifi-
cantly reduced after treatment with GA or LC. These results
demonstrated an anti-inflammatory effect of GA, and LC.The anti-inflammatory effects of LC are previously shown in
different animal models of inflammation.29
Parallel to acute and chronic inflammatory processes, the
pathophysiology of OA development includes an active biolog-
ical process of matrix degradation, leading to the release of
MMPs and eventually cartilage loss. MMPs can degrade
native fibrillar collagens of types I, II, III, V, and XI, being
involved in various pathologic conditions.30 Many studies
have reported increased activities of MMP-3 and MMP-13 in
human OA cartilage as well as experimental animal models
of OA. IL-1b was shown to diminish the expression of type
2 collagen and aggrecan, and increases the expression of
MMP-1, -3, and -13.30
In accordance with previous studies,31 we found that the
synovial fluid level of MMP-13 was elevated in the untreated
MIA induced OA group. Meanwhile, the levels of MMP-13
were significantly inhibited by GA, LC treatment; suggesting
the potential of these agents as one of the DMOADs in OA
treatment.
Cartilage oligomeric matrix protein is one of the essential
components of the extracellular matrix of the cartilage. COMP
regulates the cellular proliferation, apoptosis and cellular
attachment in the cartilaginous tissue.32 COMP has shown
promise as a potential biomarker for monitoring progression
of cartilage destruction, for evaluating cartilage effects of ther-
apy, and as a prognostic tool reflecting cartilage damage.33
Serum COMP levels can be detected quite early during the
inflammatory process, in the synovial fluid and in the blood-
stream, even before radiographic joint lesions and irreversible
damage appear.32
The elevation of COMP inMIA induced OA group was con-
comitant with that of other animalmodels of arthritis.34 Joosten
et al., previously demonstrated that therapeutic intervention
which ameliorated cartilage destruction normalized serum
COMP levels in murine CIA, whereas treatment which only
reduced signs of inflammation did not affect COMP levels.35
Glucosamine is one of the most frequently used alternatives
worldwide due to their chondroprotective properties. Despite
being considered effective by many research groups, contro-
versy surrounds the use of glucosamine in OA. In long-term
studies, no benefit of glucosamine for pain was found. The
dose used in animal model was found to be much higher than
that obtained through the oral ingestion of supplements.36
Furthermore, in obese and diabetic patients glucosamine
may cause alteration in glucose metabolism.36
In conclusion, L-carnitine is shown to be as effective as glu-
cosamine in lowering IL-1b [biochemical marker of inflamma-
tion], MMP-13 and COMP [markers of cartilage destruction]
in OA induced rat model. These results suggest a promising
use of L-carnitine as a potential DMOAD.Conflict of interest
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